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Abstract
Background—Activated platelets have previously-unrecognized mechanisms of post-
transcriptional gene expression that may influence hemostasis and inflammation. A novel pathway
involves splicing of pre-mRNAs in resting platelets to mature, translatable mRNAs in response to
cellular activation.
Objectives—We asked if bacterial products and host agonists present in the septic milieu induce
tissue factor pre-mRNA splicing in platelets from healthy subjects. In parallel, we asked if spliced
tissue factor mRNA is present in platelets from septic patients in a proof-of-principle analysis.
Patients/Methods—Tissue factor pre-mRNA and mRNA expression patterns were
characterized in platelets from septic patients and in platelets isolated from healthy subjects
activated with bacteria, toxins, and inflammatory agonists. Procoagulant activity was also
measured.
Results and Conclusions—Live bacteria, staphylococcal α-toxin, and lipopolysaccharide
induced tissue factor pre-mRNA splicing in platelets isolated from healthy subjects. Toxin-
stimulated platelets accelerated plasma clotting, a response that was blocked by a previously-
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characterized splicing inhibitor and by an anti-tissue factor antibody. Platelets from septic patients
expressed spliced tissue factor mRNA, whereas it was absent from unselected and age-matched
control subjects. Tissue factor-dependent procoagulant activity was elevated in platelets from a
subset of septic patients. Thus, bacterial and host factors induce splicing of tissue factor pre-
mRNA, expression of tissue factor mRNA, and tissue factor-dependent clotting activity in human
platelets. Tissue factor mRNA is present in platelets from some septic patients, indicating that it
may be a marker of altered platelet phenotype and function in sepsis and that splicing pathways
are induced in this syndrome.
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INTRODUCTION
Platelet number and function are altered in sepsis, a complex systemic syndrome of injurious
host inflammatory and thrombotic responses to infection [1–10]. Platelet activation – a
general term for a daedal group of functional activities that traditionally includes adherence,
aggregation, and rapid secretion of preformed thrombotic and inflammatory mediators
[11,12] – may be a ubiquitous effector mechanism in the complex pathophysiology of septic
syndromes (reviewed in [1,3,4,8,10]). This is consistent with evolving concepts of platelets
as inflammatory cells, in addition to their activities as cellular effectors of hemostasis
[12,13].
In addition to intensely-studied adhesive and secretory events that occur rapidly and
transiently after cellular activation, platelets have newly-recognized functional responses
that may be important in sepsis and other inflammatory and thrombotic disorders [13].
These changes in function and phenotype are induced by “outside-in” signals delivered via
surface receptors and involve intracellular biochemical cascades, and thus also represent
activation responses. Post-transcriptional gene expression triggered by cellular activation is
among these novel activities [13]. For example, stimulation of platelets with physiological
agonists induces translation of endogenous repressed messenger RNAs (mRNAs), leading to
rapid and sustained synthesis of protein products with activities relevant to thrombosis and
inflammation (“signal-dependent translation”) [13,14]. Remarkably, the platelet
transcriptome also contains pre-messenger RNAs (pre-mRNAs)1, and activation of platelets
leads to splicing of constitutively-expressed pre-mRNAs into mature transcripts that are
translated into functional proteins [15–18]. One of these pre-mRNAs encodes tissue factor
(TF) [18], which initiates coagulation by inducing a proteolytic cascade that culminates in
generation of thrombin and conversion of fibrinogen to fibrin [19]. TF activity is induced in
experimental and clinical sepsis, and is a central mechanism in pathologic clotting in this
disorder [20–24]. Procoagulant activity mediated by TF, together with cellular activation of
platelets, results in deposition of platelet-fibrin thrombi in microvessels. This may then lead
to inadequate tissue perfusion, vascular injury, and – potentially – end organ failure and/or
multiple organ dysfunction in sepsis [1,4,9,10,20,23]. Contributions of endogenous platelet
TF activity to these events are unexplored, and it is unknown if expression of TF pre-mRNA
and mRNA transcripts is altered in sepsis.
In the current study, we examined TF pre-mRNA and mRNA expression and TF
procoagulant activity in platelets isolated from healthy subjects before and after activation
with bacteria, bacterial toxins, thrombin, or platelet activating factor (PAF). These agonists
were examined because they are present and/or are generated in the internal milieu of human
sepsis (reviewed in [10]). Because platelets may be ubiquitously-activated in human subjects
with sepsis [1], we also performed an initial characterization of TF transcripts in platelets
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isolated from septic patients as an in vivo proof-of-principle analysis, with the hypothesis
that mature TF mRNA is expressed in platelets from subjects with this syndrome. We found
that spliced TF mRNA is present in circulating platelets from septic patients, that platelet-
dependent procoagulant activity is enhanced in samples from septic subjects, and that
bacterial toxins and host inflammatory factors may contribute to these phenotypic and
functional alterations.
METHODS
Platelet Isolation and Activation with Toxins, Bacteria, and Mediators
Detailed methods are described in supporting online text. CD45 leukocyte-depleted human
platelets were isolated from healthy volunteers, patients with sepsis, or control patients and
suspended in medium (1×109/ml) as previously described [14, 15, 18]. The protocols for this
study were reviewed and approved by the University of Utah School of Medicine
Institutional Review Board. Platelets from healthy subjects were left quiescent or activated
with α-toxin (10ng/ml; List Biological Laboratories Inc.) or lipopolysaccharide (LPS, strain
0111:B4; 100 ng/ml; Sigma) [25, 26]. In some studies, platelets were pre-incubated (30 min)
with vehicle alone or with Tg003 (Calbiochem), a previously-reported inhibitor of the
platelet splicing pathway [18]. In a second group of experiments, platelets were
preincubated (15 min) with CLI-095 (also called TAK-242) [27] or with vehicle (DMSO)
prior to treatment with LPS or α-toxin. In additional studies platelets were activated with
PAF (C-16 PAF, Biomol) or thrombin (Sigma, St. Louis, MO) as described in “Results”.
Bacterial Incubation
Platelets were incubated alone or in suspension with Staphylococcus aureus or Escherichia
coli at a bacterium to platelet ratio of 1:10. Bacteria were isolated from blood cultures from
septic patients.
Pre-mRNA and mRNA Detection
mRNA was detected using polymerase chain reactions (PCR), as previously described
[15,18]. Primers that targeted TF exonic sequences four (5'-
CTCGGACAGCCAACAATTCAG-3') and five (5'-CGGGCTGTCTGTACTCTTCC-3'),
thus spanning intron four, were used to identify unspliced and spliced TF transcripts using
previously established conditions and criteria for detection [18]. For all samples, PCR
conditions were set to 35 cycles to determine if the mature transcript (i.e., 297 bp) was
present or absent at this threshold. To rule out contribution by contaminating leukocytes, we
also assessed TF and integrin subunit αIIb mRNA expression levels (Supporting Figs 1–3)
and monocyte chemotactic protein 1 (MCP-1) mRNA expression (Supporting Fig 4).
TF-dependent Procoagulant Activity and Clotting
Platelets or monocytes from healthy controls were stimulated with LPS, α-toxin, or thrombin
in the presence of Tg003 or its vehicle. Preparation of platelet membranes and
microparticles and assays of procoagulant activity were accomplished as described [18].
Septic Patients
TF pre-mRNA and mRNA expression patterns were examined in platelets from forty six
patients meeting consensus criteria for sepsis [28] after approval of the study by the
University of Utah School of Medicine Institutional Review Board and informed consent
prior to study enrollment. Blood samples for analysis of platelet TF patterns were collected
within 72 hours of admission to the Medical Intensive Care Unit (MICU). In a subset of 16
patients, platelets were collected within the first 72 hours and at later time points in serial
Rondina et al. Page 3













fashion. TF pre-mRNA and mRNA expression patterns were examined in unstimulated
platelets from healthy, medication-free volunteers (age 18–50) in parallel with each assay of
platelets from septic subjects. In addition, we also examined platelets from non-hospitalized,
healthy volunteers age-matched to the septic patients.
Statistical Analyses
Each experimental result reflects at least 3–5 experiments. For all analyses, continuous
variables were assessed for normality and if distributions were normal, parametric t-tests
were used. If distributions were not normal, Wilcoxon Rank Sum tests were used.
Categorical variables were compared using the Fisher’s Exact test. Significance was
predetermined at p<0.05. Categorical variables were compared using the Fisher’s Exact test
and t tests for comparison of continuous variables. The three study groups (unselected
healthy volunteers, age-matched healthy volunteers, and septic patients) were compared on
the dichotomous outcome of TF splicing using Logistic regression analyses to determine
odds ratios (OR) controlled for the confounder of age.
RESULTS
Bacterial Pathogens and Host Factors Induce TF Pre-mRNA Splicing, Expression of TF
mRNA, and Generation of TF-dependent Procoagulant Activity by Human Platelets
We first characterized the pattern of unspliced and spliced TF transcripts in platelets from
healthy subjects using primers that flank intron 4. This strategy was chosen because intron 4
is the shortest intron in the TF pre-mRNA (Fig 1A), and is thus most tractable to
amplification of the pre-mRNA (904bp) and mRNA (297bp) sequences. In previous studies,
we validated this approach and also detected TF transcripts using primers that span other
introns [18]. In the current studies the unspliced pre-mRNA was uniformly present, and the
mature transcript absent, in unstimulated platelets from healthy volunteers (Fig 1B; also see
Figs 2A,3B,4, and Supporting Figs 1–3). This is consistent with previous results in which
we verified the presence of the pre-mRNA by amplification and sequencing of the entire
transcript and by in situ detection of the pre-mRNA in quiescent platelets, and also found
that the spliced mRNA is not present under basal conditions [18]. We also previously found
that the TF pre-mRNA is spliced to the mature, translatable mRNA in platelets from normal
subjects when platelets adherent to fibrinogen are activated with nanomolar concentrations
of thrombin [18], which is generated in sepsis and may be a key mediator of platelet
activation in septic patients [10,20,22,23]. In the current study we confirmed by quantitative
RT-PCR (qRT-PCR) that activated platelets splice TF pre-mRNA into mature mRNA
(Supporting Figs 1–3). In addition, supporting figs 1–4 conclusively demonstrate that TF
pre-mRNA splicing events detected in our platelet preparations were not due to the presence
of contaminating leukocytes.
To determine if microbial stimuli can also induce splicing activity and consequent
processing of the TF pre-mRNA to the mRNA transcript, we examined bacterial toxins that
can activate host effector cells. E. coli LPS, in concentrations of 10–1000ng/ml, did not
directly increase P-selectin expression on the surfaces of platelets after a 60 min incubation
(data not shown). Nevertheless, LPS induced splicing, yielding mature TF mRNA in isolated
platelets within 30 minutes that increased over time (Fig 1B). Generation of mature TF
mRNA was inhibited by Tg003 (Fig 1C), which interrupts activation-dependent splicing of
TF pre-mRNA by blocking activity of Cdc2-like kinase 1, a key enzyme in the splicing
pathway [18]. These results are similar to findings of Shaskin et al [29] who recently
reported time-dependent splicing of IL-1β pre-mRNA in human platelets induced by LPS. In
addition, we found that LPS-induced splicing of TF pre-mRNA was blocked by a small
molecule inhibitor, CLI-095 (Figure 1D), that suppresses cellular responses triggered by
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TLR4 engagement by selectively interrupting signaling mediated by the intracellular domain
of the toll-like receptor [27]. This is consistent with activation of the Cde2-like kinase
splicing pathway [18] by a mechanism that involves molecular interactions at the
cytoplasmic tail of TLR4.
In our previous studies, time-dependent splicing of the TF pre-mRNA transcript in
thrombin-stimulated platelets was paralleled by enhanced procoagulant activity and
accelerated TF-dependent clotting, indicating translation of the mature mRNA and synthesis
of the functional protein product [18]. Similarly, we found that plasma clotting time was
shortened in the presence of membranes isolated from LPS-stimulated platelets (Fig 1C,
right panel). Tg003 reversed this response, confirming that accelerated clotting depends on
pre-mRNA splicing. Furthermore, a neutralizing antibody against TF also reversed the
shortened clotting times (Fig 1C, right panel).
We compared TF-dependent procoagulant activity expressed by stimulated platelets to that
of monocytes, a major cellular source of TF in sepsis and other prothrombotic conditions
[19,22,23]. For these studies, the ratio of procoagulant activity in platelets versus monocytes
was determined using cell numbers that reflected differential platelet and monocyte numbers
in the volunteer donor’s blood on the day of the experiment. At 120 min of stimulation the
procoagulant activity of thrombin-stimulated platelets was equal or greater to that of
monocytes (Fig 1E). In contrast, when LPS was the agonist, the procoagulant response of
monocytes was much greater than that of platelets (Fig 1E). This finding suggests that local
generation of TF-dependent procoagulant activity depends on the agonist and cell type in
sepsis, and that the contributions by platelets may be important depending on the stimulus
and time of activation of target cells. Furthermore, platelet generation of TF-dependent
procoagulant activity may be additive to that of other key cells [19,23].
Staphylococcal infections are common initiators of sepsis and septic complications,
including thrombosis and microvascular fibrin deposition [10]. A factor with potentially
lethal activities that is released by S. aureus [25], α-toxin, induced TF pre-mRNA splicing in
platelets (Fig 2A). Higher concentrations of α-toxin did not further increase TF pre-mRNA
splicing in platelets (data not shown). We also found that membranes from platelets
stimulated with α-toxin shortened plasma clotting time (Fig 2B). Accelerated clotting time
was blocked when the platelets were pretreated with the splicing inhibitor Tg003 or a
neutralizing antibody against TF (Fig 2B). In an initial experiment CLI-095, which blocked
LPS-inhibited splicing (Figure 1D), did not inhibit splicing triggered by α-toxin (not shown).
In additional experiments, we found that E. coli or S. aureus adhere to human platelets and
induce TF pre-mRNA splicing within 30 minutes, a response that increased over time (Fig
3A, 3B, and data not shown). We also found that incubation of whole blood from a control
subject with S. aureus induced coagulation and that spliced TF mRNA was present in
platelets extracted from the clot, whereas only unspliced TF pre-mRNA was present in the
uncoagulated blood sample in the absence of bacteria (Supporting Fig 5).
Bacteria and bacterial products induce generation of endogenous host mediators in clinical
and experimental sepsis [10]. In addition to thrombin, PAF is synthesized in the septic
milieu and activates platelets and leukocytes in sepsis [10]. As with thrombin [18], PAF
triggered splicing of TF pre-mRNA in a time- and concentration-dependent fashion
(Supporting Fig 6).
Platelets Isolated from Septic Patients Express Spliced TF mRNA
Platelet activation is a common and perhaps ubiquitous feature of sepsis [1,3,4,8–10], and
bacterial factors and host mediators induce splicing of TF pre-mRNA by platelets from
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control subjects (Figs 1–3;Supporting Figs 5,6). Therefore, we examined platelets from
septic patients for spliced TF mRNA as an initial proof-of-principle analysis of in vivo
relevance of our in vitro findings. We prospectively enrolled 46 patients (Table 1) who met
consensus criteria for sepsis, the majority of whom (>85%) had the complicated syndromes
of severe sepsis or septic shock [28,30]. There were broad ranges of platelet and leukocyte
counts and APACHE II scores (a severity index based on multiple variables in critical
illness), as might be expected for a relatively small study population that included the full
clinical spectrum of sepsis (Table 2).
We found that platelets in samples from 54% of septic patients expressed mature, spliced TF
mRNA in blood collected within 72 hours of admission to the ICU or in one or more later
samples (see below) (Fig 4A, Table 2). We observed a similar frequency of TF pre-mRNA
splicing when mRNA expression patterns were assessed by qRT-PCR (data not shown). In
contrast, platelets isolated from 65 healthy young volunteers (mean ± SD age = 34 ± 9 years,
range 18–50 years) examined in parallel side-by-side assays exclusively expressed unspliced
TF pre-mRNA in the absence of an activating agonist such as thrombin or PAF (Fig 4 and
data not shown). This result is consistent with previous studies [18], and with analysis of the
transcripts in platelets from healthy volunteers in in vitro experiments in this study (Figs 1–
3, Supporting Figs 1–3, and data not shown). In addition, unactivated platelets isolated from
a group of 10 randomly selected, older healthy controls (mean ± SD age = 58.1±11 years,
range 40–74 years) age-matched to the septic subjects (Table 1) exclusively expressed
unspliced TF mRNA (data not shown).
In a subset of patients (n=16) we were able to collect serial blood samples to determine if the
species of TF transcripts in platelets changed during the course of the septic episode. Fig 4B
illustrates an example, in which platelets from a patient with aspiration pneumonia and
sepsis due to Enterococcus faecalis were examined in serial fashion. Both unspliced pre-
mRNA and mature, spliced mRNA were detected on days 1 and 3 but only spliced mRNA
was detected on day 5. At day 10, when sepsis had resolved and this patient had improved
clinically, the patient’s platelets only expressed unspliced TF pre-mRNA – a pattern
equivalent to that of unactivated platelets from control subjects (Fig 4B). Serial analysis also
revealed that platelets from some patients did not initially express spliced TF mRNA at the
time of ICU admission but mature TF mRNA was subsequently detected at later times
during the course of sepsis (data not shown). Of 16 patients in whom serial sampling was
performed, 13 expressed spliced TF mRNA in at least one analysis (Fig 4B, pie chart).
Septic patients who were ≥65 years, had an APACHE II score >20, or had documented
bacteremia were more likely to express mature, spliced TF mRNA in one or more samples
(single or serial analysis) (Table 2). The odds of mature, spliced TF mRNA being present in
platelets isolated from septic patients within 72 hours of ICU admission also increased with
age ≥65 and APACHE II score >20. In addition, patients with sepsis whose platelets
expressed mature TF mRNA at one or more time points were more likely to die prior to
hospital discharge, regardless of age. Nevertheless, the confidence intervals for these trends
and subgroups were wide. This may be due in part to a relatively small sample size and
inclusion of patients with a spectrum of septic syndromes.
Platelets Isolated from Septic Patients have Enhanced TF-Dependent Procoagulant
Activity
We were unable to collect enough blood from patients to retrieve sufficient numbers of
platelets for simultaneous analysis TF pre-mRNA splicing and procoagulant activity.
Therefore, we measured TF-dependent procoagulant activity expressed by platelets from 5
additional septic patients and 5 healthy volunteers. We found that TF activity was increased
in membrane preparations from platelets isolated from patients with sepsis compared to
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platelets from healthy subjects assayed in a side-by-side, parallel fashion in order to control
for individual and day-today variability (Fig 5). The mean TF activity of combined platelet
membrane and microparticle fractions from platelets isolated from septic patients (45.9±29.6
pM) was significantly higher than that in preparations from control subjects (11.1±6.3 pM;
p=0.03). TF activity was also higher in preparations from septic patients versus control
subjects when platelet membrane and microparticle fractions were examined separately,
although the difference achieved statistical significance in the microparticle analysis only
(Fig 5). Enhanced procoagulant activity associated with platelets from septic patients
compared to controls (Fig 5) is consistent with expression of mature, spliced TF mRNA in
platelets from septic subjects (Fig 4, Table 2), although other mechanisms could also
account for this observation [19,23].
DISCUSSION
Our findings demonstrate that platelets from some patients with sepsis express mature,
spliced TF mRNA, in contrast to platelets from control subjects. While inflammatory
conditions such as sepsis can alter transcript expression and other characteristics of
circulating platelets by inducing changes in megakaryocyte function [31,32], our parallel in
vitro studies suggest a mechanism that may operate independently, or in concert, involving
systemic activation-dependent splicing of TF pre-mRNA and translation of the spliced,
mature transcript by human platelets. Splicing in the circulation may occur when platelets
encounter microbial toxins, live bacteria, or endogenous host factors that are generated in
the septic milieu. The studies also suggest that sepsis-driven splicing may contribute to
enhanced TF-dependent procoagulant activity of platelets sequestered in the
microvasculature of affected patients, potentially contributing to dysregulated hemostasis
and inflammation. These are central features of the pathobiology of septic syndromes
[4,10,20].
We previously found that the transcriptome of quiescent platelets isolated from healthy
volunteers includes pre-mRNAs, and that activation of platelets with thrombin induces
spliceosomal activity and processing of unspliced transcripts to mature, translatable mRNAs
[15,18]. This represents a novel and unexpected activity of human platelets [13,15,33]. In
addition to TF [18] the unspliced transcripts that are constitutively present in resting human
platelets include IL-1β [15], which encodes a pleiotropic cytokine important in sepsis and
other inflammatory disorders [10,20]. Stimulation of platelets with thrombin while the cells
are adherent to fibrinogen, conditions that model events that occur in micro-thrombi in
inflamed vessels in sepsis [4,10,20], induces splicing of TF pre-mRNA, expression of TF
mRNA, and translation of the mRNA into TF protein [18]. Interruption of pre-mRNA
splicing or translation of the mature mRNA prevents increased TF protein expression in
activated platelets [18]. Inhibition of TF pre-mRNA splicing also prevents TF-dependent
procoagulant activity from accumulating in activated platelet membranes and microparticles
[18]. It is possible that “de-encryption” [34] may be required for full TF activity in these
membranous domains. In addition to our original observations, other investigators have
reported that human platelets synthesize TF protein [35–37] and confirmed that activating
signals induce splicing of pre-mRNAs, including the TF precursor transcript, in human
platelets [29,36,37].
In this study we demonstrate that bacterial factors that induce functional alterations in target
cells in vitro and in vivo [10,25,26] are agonists for splicing of TF pre-mRNA, accumulation
of mature TF mRNA, and generation of TF-dependent procoagulant activity by platelets
from normal subjects. We found that LPS induces time-dependent TF pre-mRNA splicing
and splicing-dependent procoagulant activity (Fig 1). Induction of splicing and post-
transcriptional TF expression in platelets stimulated by LPS identifies a new mechanism by
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which LPS can trigger procoagulant events in sepsis or in localized infections caused by
gram negative bacteria [23,26]. This may occur if LPS is released into the blood
systemically or locally or, potentially, by direct encounters between platelets and gram
negative pathogens (Fig 3).
LPS-induced splicing of pre-mRNA transcripts is consistent with multiple observations
demonstrating that human and mouse platelets express members of the toll-like receptor
family, including TLR4 [10,29] (reviewed in [38]). This is one molecular mechanism by
which platelets act as “sentinels” for microbes and recognize, respond to, and participate in
clearance of bacteria and other pathogens [4,10,12,38]. In vivo studies indicate that human
and murine platelet TLR4 is functional, and that it mediates LPS-induced thrombocytopenia,
cytokine production, and other cellular responses [29,38–42]. Nevertheless, mechanisms by
which engagement of TLR4 induces alterations in function and phenotype of platelets
(reviewed in [38]), are incompletely defined. In some reports LPS did not induce
aggregation, secretion, or surface translocation of P-selectin (CD62P) [41,43] whereas in
others these responses were detected depending on incubation time and other variables
[29,39,42]. While TLR4 signaling in platelets may be “unconventional” [41], recent
observations indicate that LPS-induced activation of murine platelets requires myD88, a key
intracellular component of TLR4-mediated signaling cascades, and that myD88 is present in
human platelets [42]. Engagement of TLR4 by LPS triggers dimerization and association of
myD88 with the intracellular TIR (toll/IL-1 receptor) domain of TLR4, followed by
additional signal transduction events [10,44]. We found that a small molecule inhibitor that
selectively blocks TLR4 signaling and that may target the TIR domain [27] interrupts
splicing of TF in LPS-stimulated platelets (Figure 1D). This result suggests that interaction
of the TIR domain with myD88 and/or other adaptor proteins is a component of the
molecular mechanism leading to LPS-induced activation of the Cdc2-like kinase1 pathway
and spliceosomal function in human platelets (Figure 1) [15,18,29]. This possibility remains
to be further explored, and additional “downstream” signaling intermediates that link the
cytoplasmic domain of TLR4 to the splicing pathway remain to be defined.
We also found that α-toxin from S. aureus, a hydrophilic molecule that is one of the most
frequent toxins of bacterial origin encountered by humans [25], induces splicing of TF pre-
mRNA by human platelets. Staphylococcal α-toxin activates cells by aggregating to form
pores in the plasma membrane rather than via surface receptors [25]. Post-transcriptional
processing of TF pre-mRNA by platelets in response to α-toxin, and subsequent generation
of procoagulant activity by platelets activated by α-toxin, establish a new pathogenetic
mechanism that is potentially relevant to sepsis driven by staphylococcal pathogens. We also
found that intact S. aureus microorganisms induce pre-mRNA splicing by platelets,
indicating that direct encounters with the pathogen in the blood or at vascular surfaces may
activate this response.
Together, our experiments demonstrate that both bacteria and bacterial toxins – the primary
agents of sepsis – can directly induce expression of mature TF mRNA by human platelets.
This may then result in translation of the mRNA and synthesis of TF protein, contributing to
cascades of procoagulant activity, fibrin deposition, and proinflammatory signaling
[10,22,23,45]. In addition, host-derived mediators that are also present in the septic milieu
[10,20–24], such as PAF (Supporting Fig 6) or thrombin ([18]; Fig 2), also trigger splicing
of TF pre-mRNA and accumulation of the mature mRNA transcript by target platelets.
Therefore, under the pathologic conditions of sepsis splicing of TF pre-mRNA in platelets
may be inappropriately induced by a variety of agonists and, indeed, “misplaced” as
suggested by others [33].
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To explore the possibility that spliced TF mRNA is expressed by human platelets in vivo, we
performed an initial study in platelets from septic patients. The rationale was two-fold. First,
platelet activation is a common feature of septic syndromes [1,4,9,10], suggesting that – if
activation-dependent splicing occurs in circulating platelets in vivo – sepsis might be an
index condition in which to detect it. Second, murine models of sepsis were not appropriate
for this question because mouse platelets do not express TF pre-mRNA [46]. While other
pre-mRNAs and a splicing pathway may be conserved in murine platelets, differences in
hemostatic and inflammatory mechanisms clearly exist [47,48]. Thus, for an initial in vivo
analysis of spliced TF transcripts in platelets, studies of samples from human subjects with
clinical sepsis were necessary. We found that mature TF mRNA was expressed in platelets
isolated from 60% of septic patients with documented bacteremia (Table 2), consistent with
activation-dependent splicing triggered by bacteria and/or bacterial products in vitro (Figs
1–3). This is a previously-unrecognized phenotypic feature of platelets from patients with
sepsis. We also found that spliced TF mRNA is present in platelets from some septic
patients without documented bacteremia (Table 2), consistent with activation of platelets by
host factors such as thrombin or PAF alone or in concert with circulating microbial toxins
[10]. In contrast, we found that platelets from control subjects, including a subset of healthy
volunteers age-matched to septic patients in this study, expressed only unspliced TF pre-
mRNA. These results are similar to our original findings that platelets from healthy
volunteers exclusively express unspliced TF pre-mRNA [18]. Similarly, others reported that
only unspliced TF pre-mRNA is present in control, unactivated human platelets and that,
upon cellular activation, the mature TF mRNA transcript is generated and TF protein is
synthesized as a result of splicing [36,37]. In preliminary studies that are ongoing, we also
found that platelets from subjects at risk for deep vein thrombosis after knee or hip surgery
expressed only unspliced TF pre-mRNA (Rondina MT et al. unpublished observations).
Thus, while we predict that platelets from patients with other inflammatory or prothrombotic
conditions besides sepsis may also express spliced TF mRNA, our findings in this study
indicate that specific stimuli induce expression of spliced TF mRNA by platelets in septic
syndromes. Increased TF-dependent procoagulant activity of platelets from a subgroup of
septic patients (Fig 5), albeit a small sampling, is consistent with synthesis of TF protein
from spliced TF mRNA. We cannot, however, exclude other variables such as in vivo
binding of procoagulant TF-bearing microparticles to circulating platelets [23] from this
study alone.
Our findings also raise a number of other important issues including effects of comorbidities
[37,49], the possibility that constitutive endogenous tissue factor mRNA and/or protein
[35,50] are present in platelets from some septic patients, and the effects of variables such as
drugs and antithrombotics, specific pathogens, levels of endogenous host factors that can
induce splicing, and changes in megakaryocyte function in response to inflammatory
stimuli. Whether more severe sepsis induces greater amounts of mature TF mRNA and its
corresponding protein is also not known. Additional quantitative studies of TF transcript
profiles in platelets from patients with sepsis, post-surgical deep vein thrombosis, and acute
lung injury have been initiated to begin to address these issues (Rondina MT, Schwertz H,
Weyrich AS, et al, unpublished observations). Why mature TF mRNA and evidence for
splicing was not detected in platelets from all subjects with sepsis – if platelet activation is
ubiquitous in this condition [1,4,9,10] – is not yet clear. One explanation may be the
presence of endogenous splicing inhibitors [15] that modulate the process in the cells of
some subjects with sepsis. Another may be that pre-mRNA splicing is far more prevalent in
platelets sequestered in the local milieu of peripheral vascular beds [10] than in those we
retrieved from the systemic circulation.
Although largely unexplored, recent reports indicate that mRNA expression patterns differ
in circulating platelets from healthy subjects and those with disease [32,51–55]. Thus, it is
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possible that expression of mature TF mRNA, alone or in combination with alterations in
expression of other transcripts that undergo post-transcriptional processing in activated
platelets [13,15–18], may be a signature of sepsis and other inflammatory and prothrombotic
disorders in some patients.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. LPS induces splicing of TF pre-mRNA by human platelets
(A) The intron-exon structure of the unspliced TF pre-mRNA and the mature, spliced TF
mRNA are shown in diagrammatic form. Primers for exons 4 and 5 that span the intervening
intron (bracket and asterisk) were constructed and used to examine platelets for unspliced
and spliced TF mRNA transcripts as previously described [18]. (B) Platelets isolated from
healthy controls were incubated in medium alone or with LPS for 30–240 minutes. The box-
stick diagrams to the right identify human pre-mRNA for TF (pHTF) and mature mRNA for
TF (mHTF) based on PCR analysis of the exon 4–5 region outlined in (A) and Methods.
Size markers (M) are shown on the left and a lane without PCR primers (Neg. PCR) is
shown on the right. The transcript expression patterns shown in this figure are representative
of three independent experiments. (C) Platelets from healthy controls were assayed at time
zero (second lane) or were activated with 100 ng/ml of LPS for 120 minutes in the presence
or absence of the splicing inhibitor Tg003. Left Panel: TF mRNA expression patterns were
examined as in (B). Right panel: Membranes from platelets preincubated with Tg003 or
control buffer and then activated with LPS were added to human plasma and clotting times
were measured in the presence or absence of a neutralizing antibody against TF. The bars
represent the mean±SEM for four independent experiments. The asterisk (*) indicates a
significant difference (p<0.05) between activated platelets and quiescent or inhibitor-treated
platelets. (D) Platelets isolated from healthy subjects were analyzed at baseline (lane 2) or
after stimulation with LPS (100ng/ml, 120 min) following preincubation (15 min) in buffer
alone (lane 3), with CLI-095 dissolved in DMSO (lanes 4, 5), or with the same final
concentrations of DMSO (lanes 6, 7). TF pre-mRNA and mRNA were analyzed as in B and
C. CLI-095, an inhibitor of signaling via TLR4 [27], partially blocked TF splicing at the low
concentration (2 μm; lane 4) and almost completely blocked it at a higher concentration (3
μm; lane 5). This figure is representative of three experiments. (E) Isolated platelets
(2.1+0.2 ×109) or monocytes (4.0+0.03 ×106) were incubated with LPS (100 ng/ml) or with
thrombin (0.1 U/ml) for 120 minutes. The number of platelets and monocytes for each study
were based on the number of each cell type present in 10 ml of the volunteer donor’s blood,
which was determined by differential platelet and monocyte counts assessed on the day of
the experiment. TF-dependent procoagulant activity associated with isolated cell membranes
was measured in 3 independent experiments. The bars indicate mean±SEM of the
experiments and the data are displayed as fold increase over baseline TF activity in
unstimulated membranes from platelets and monocytes.
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Figure 2. α-toxin induces splicing of TF pre-mRNA and expression of TF-dependent
procoagulant activity by human platelets
(A) TF mRNA expression patterns were assessed in platelets from healthy controls that were
assayed at time zero (lane 2) or were activated with staphylococcal α-toxin for 120 minutes
(lane 3) as described in Figure 1. This gel is representative of 3 independent experiments.
(B) Platelets from healthy volunteers were incubated with control buffer or activated with α-
toxin for 120 minutes in the presence or absence of Tg003. Plasma clotting was measured as
described in Figure 1C. The bars represent the mean ± SEM for four independent
experiments and the asterisk (*) indicates a significant difference (p<0.05) between
activated platelets and quiescent or inhibitor treated platelets.
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Figure 3. E. coli and S. aureus induce splicing of TF pre-mRNA in human platelets
(A) Platelets isolated from healthy controls were incubated in medium alone (control) or in
the presence of S. aureus or E. coli bacteria for 30 minutes. The platelets and bacteria were
then fixed in suspension and subsequently stained with Alexa 488 phalloidin (for F-actin;
green staining in platelets) and TOPRO-3 (for DNA; magenta in bacteria). This figure is
representative of multiple independent studies. (B) TF pre-mRNA and mRNA expression
patterns were assessed in platelets from healthy controls that were incubated with E. coli or
S. aureus for 30 minutes. This gel is representative of 3 independent experiments.
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Figure 4. Platelets isolated from patients with sepsis express spliced TF mRNA
(A) Patterns of TF pre-mRNA and mature TF mRNA expression were examined in platelets
from healthy control donors and septic patients as outlined in Figure 1. No exogenous
activating agonist was added. A representative experiment examining platelets isolated from
a healthy control and a septic patient, studied in parallel, is shown. The pie chart below the
gel illustrates the number of platelet preparations from septic patients (46 total), isolated
within 72 hours of ICU admission, that expressed unspliced or spliced TF transcripts.
Unspliced and spliced transcripts were present together in platelets from some septic
subjects as shown, consistent with patterns detected in vitro (Figures 1–3). (B) A
representative example of serial examination of platelets isolated from a septic patient at day
1, 3, 5, and 10 post-admission to the ICU. Platelets from control donors were assayed in
parallel with each sample from the patient; one representative blot is shown in lane 2. The
pie chart below the gel illustrates the total number of septic patients (13 of 16) whose
platelets expressed spliced TF mRNA on at least one day during the septic episode and serial
analysis.
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Figure 5. Platelets from patients with sepsis have increased TF-dependent procoagulant activity
compared to activity associated with platelets from control subjects
TF-dependent procoagulant activity was measured using membranes and microparticles
isolated from platelets in samples from healthy control subjects (n=5) and patients with
sepsis (n=5). No exogenous activating agonist was added. Samples from control subjects
and septic patients were assayed in side-by-side fashion on the same day. The paired
samples are indicated by matching symbols in each panel. The single asterisk (*) indicates a
statistical significance of p=0.03. The double asterisks (**) denotes a statistical significance
of p<0.01.
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Table 1
Patient Characteristics (n=46)*
Mean age (yrs) 57±17
Median age (yrs) 57
Male 54%
APACHE II Score 25.6±9.2
Platelets count (K/ul) 232±136
WBC (K/ul) 17.8±10.3
Bacteremia 52%
MICU LOS (days) 6.7±9.7
In-hospital mortality 13%
*
Values indicate mean ± standard deviation.
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Table 2
Clinical Features of Patients in Which Spliced, Mature TF mRNA Was or Was Not Detected in Circulating
Platelets*




Odds Ratio (95% CI) Odds Ratio (95% CI) Adjusted
for Age
Number of patients 25 (54%) 21 (46%) -- --
Age ≥65 10 (40%) 4 (19%) 2.77 (0.63, 14.74) --
Female† 12 (48%) 9 (43%) 1.23 (0.33, 4.64) 1.40 (0.37, 5.66)
APACHE II >20* 21 (84%) 11 (52%) 4.60 (1.03, 25.02) 4.06 (0.87, 22.69)
Bacteremia§ 15 (60%) 8 (37%) 2.45 (0.63, 10.11) 2.45 (0.63, 10.11)
D-dimer>8.2 [units]‡ 6/19 (32%) 3/10 (30%) 1.34 (0.65, 2.91) 1.32 (0.64, 2.83)
MICU LOS (days)* 8.3 4.8 1.05 (0.97, 1.17) 1.06 (0.98, 1.18)
Survival to Hospital
20 (80%) 20 (95%) 0.21 (0.004, 2.08) 0.23 (0.004, 2.40)
Discharge
*
Platelets were isolated from patients with sepsis (identified by consensus criteria) within 72 hours of admission to the MICU. Spliced TF mRNA
was detected in platelets from one or more blood samples from 25 patients, and only the unspliced TF transcript was present in platelets from 21




D-dimer levels were only available for 29 patients upon MICU admission and study enrollment;
§
Culture data on 2 patients was unavailable.]
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